Sophos has entered into a definitive agreement to acquire the commercial software products business of Invincea, a developer of patented next-generation malware protection, from its existing shareholders for $100m plus a $20m earn-out.
Invincea has a strong presence in the US, particularly in the government, healthcare and financial services sectors.
The Invincea endpoint security portfolio prevents, detects and remediates zero-day and sophisticated attacks, and combines neural-network based machine learning and behavioural monitoring to enhance detection through artificial intelligence and stop evasive malware before damage occurs.
Sophos Chief Executive Officer, Kris Hagerman, commented: "Invincea will strengthen Sophos' next-gen endpoint protection with complementary predictive defenses that we believe will become increasingly important to the future of endpoint protection and allow us to take full advantage of this significant new growth opportunity."
The value of the gross assets of Invincea as at 31 March 2016 was $15.7 million. In the 12 months to 31 March 2016, Invincea recorded billings of $13.4 million, revenue of $9.8 million and a loss before tax of $11.8 million.